Wat is de prijs voor MultiCell Technologies, Inc. (MCET)

Het prijs van MultiCell Technologies, Inc. (MCET) is $0.00001

Wat is de marktkapitalisatie voor MultiCell Technologies, Inc. (MCET)

Marktkapitalisatie voorMultiCell Technologies, Inc. (MCET) is $50.01K

MultiCell Technologies, Inc. (MCET) Winst

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

Jaar	Winst	Wijzigen
2026 (TTM)	$-253.70	-52.03%
2014	$-528.83	-61.38%
2013	$-1.37K	0.00%

Jaar

Winst

Wijzigen

2026 (TTM)

$-253.70

-52.03%

2014

$-528.83

-61.38%

2013

$-1.37K

0.00%

Bedrijf	Winst	Winstverschil	Land
Novo Nordisk A/S NVO.US	$20.46B	-8,063,391,933.22%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	$4.64B	-1,830,164,385.94%	US
Regeneron Pharmaceuticals, Inc. REGN.US	$5.23B	-2,061,733,458.56%	US
UCB SA UCB.BR	$2.14B	-842,594,116.58%	BE
CSL Limited CSL.AX	$1.61B	-636,286,470.34%	AU

Bedrijf

Winst

Winstverschil

Land